$BCAX News

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul

BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35

Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX)

Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33

Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39

Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds

Mizuho Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $23

BTIG Maintains Buy on Bicara Therapeutics, Raises Price Target to $39

Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says

Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary

Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances

Bicara Therapeutics Q2 Earnings Call Highlights

Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript

Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth